Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

33.82 -0.79 (-2.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M ↗
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
News headline image
Netflix To $210? Here's The Biggest Price Target Changes For Friday ↗
Piper Sandler cut The Goldman Sachs Group, Inc. (NYSE: GS) price target from $430 to $410. Goldman Sachs shares fell 0.1% to $296.79 in pre-market trading. 
Via Benzinga
News headline image
Expert Ratings for Ultragenyx Pharmaceutical ↗
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Scheduled For February 10, 2022 ↗
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
Via Benzinga
News headline image
Earnings Scheduled For November 2, 2021 ↗
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
News headline image
Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know ↗
Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9%... 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Ultragenyx Pharmaceutical's Earnings Outlook ↗
Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022 ↗
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... 
Via Benzinga
News headline image
Where Ultragenyx Pharmaceutical Stands With Analysts ↗
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
News headline image
Ultragenyx Pharmaceutical: Q4 Earnings Insights ↗
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
News headline image
Ultragenyx Pharmaceutical inc (RARE) Q3 2021 Earnings Call Transcript ↗
RARE earnings call for the period ending October 2, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical ↗
Over the past 3 months, 4 analysts have published their opinion on Ultragenyx Pharmaceutical (NASDAQ: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 ↗
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
News headline image
Ultragenyx Resumes Dosing Antisense Trial In Rare Neurogenetic Disorder ↗
The FDA has removed the clinical hold on GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) GTX-102 trial for... 
Via Benzinga
News headline image
Return on Capital Employed Insights for Ultragenyx Pharmaceutical ↗
After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021 ↗
Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ: 
Via Benzinga
News headline image
Return on Capital Employed Overview: Ultragenyx Pharmaceutical ↗
After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.